150 related articles for article (PubMed ID: 12824014)
1. Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
Engler TA; Furness K; Malhotra S; Sanchez-Martinez C; Shih C; Xie W; Zhu G; Zhou X; Conner S; Faul MM; Sullivan KA; Kolis SP; Brooks HB; Patel B; Schultz RM; DeHahn TB; Kirmani K; Spencer CD; Watkins SA; Considine EL; Dempsey JA; Ogg CA; Stamm NB; Anderson BD; Campbell RM; Vasudevan V; Lytle ML
Bioorg Med Chem Lett; 2003 Jul; 13(14):2261-7. PubMed ID: 12824014
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors.
Zhu G; Conner S; Zhou X; Shih C; Brooks HB; Considine E; Dempsey JA; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
Bioorg Med Chem Lett; 2003 Apr; 13(7):1231-5. PubMed ID: 12657252
[TBL] [Abstract][Full Text] [Related]
3. Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.
Sanchez-Martinez C; Shih C; Faul MM; Zhu G; Paal M; Somoza C; Li T; Kumrich CA; Winneroski LL; Xun Z; Brooks HB; Patel BK; Schultz RM; DeHahn TB; Spencer CD; Watkins SA; Considine E; Dempsey JA; Ogg CA; Campbell RM; Anderson BA; Wagner J
Bioorg Med Chem Lett; 2003 Nov; 13(21):3835-9. PubMed ID: 14552791
[TBL] [Abstract][Full Text] [Related]
4. Studies on cyclin-dependent kinase inhibitors: indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus bis-indolylmaleimides.
Sanchez-Martinez C; Shih C; Zhu G; Li T; Brooks HB; Patel BK; Schultz RM; DeHahn TB; Spencer CD; Watkins SA; Ogg CA; Considine E; Dempsey JA; Zhang F
Bioorg Med Chem Lett; 2003 Nov; 13(21):3841-6. PubMed ID: 14552792
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.
Zhu G; Conner SE; Zhou X; Shih C; Li T; Anderson BD; Brooks HB; Campbell RM; Considine E; Dempsey JA; Faul MM; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
J Med Chem; 2003 May; 46(11):2027-30. PubMed ID: 12747775
[TBL] [Abstract][Full Text] [Related]
6. Synthetic approaches to indolo[6,7-a]pyrrolo[3,4-c]carbazoles: potent cyclin D1/CDK4 inhibitors.
Faul MM; Engler TA; Sullivan KA; Grutsch JL; Clayton MT; Martinelli MJ; Pawlak JM; LeTourneau M; Coffey DS; Pedersen SW; Kolis SP; Furness K; Malhotra S; Al-awar RS; Ray JE
J Org Chem; 2004 Apr; 69(9):2967-75. PubMed ID: 15104433
[TBL] [Abstract][Full Text] [Related]
7. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
[TBL] [Abstract][Full Text] [Related]
8. CaMK-II inhibition reduces cyclin D1 levels and enhances the association of p27kip1 with Cdk2 to cause G1 arrest in NIH 3T3 cells.
Morris TA; DeLorenzo RJ; Tombes RM
Exp Cell Res; 1998 May; 240(2):218-27. PubMed ID: 9596994
[TBL] [Abstract][Full Text] [Related]
9. Characterization of novel inhibitors of cyclin-dependent kinases.
Kent LL; Hull-Campbell NE; Lau T; Wu JC; Thompson SA; Nori M
Biochem Biophys Res Commun; 1999 Jul; 260(3):768-74. PubMed ID: 10403840
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Fåhraeus R; Laín S; Ball KL; Lane DP
Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
[TBL] [Abstract][Full Text] [Related]
12. 1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors.
Al-awar RS; Ray JE; Hecker KA; Huang J; Waid PP; Shih C; Brooks HB; Spencer CD; Watkins SA; Patel BR; Stamm NB; Ogg CA; Schultz RM; Considine EL; Faul MM; Sullivan KA; Kolis SP; Grutsch JL; Joseph S
Bioorg Med Chem Lett; 2004 Jun; 14(12):3217-20. PubMed ID: 15149678
[TBL] [Abstract][Full Text] [Related]
13. Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors p21 and p27 in human colorectal carcinoma cells.
Pan MH; Chen WJ; Lin-Shiau SY; Ho CT; Lin JK
Carcinogenesis; 2002 Oct; 23(10):1677-84. PubMed ID: 12376477
[TBL] [Abstract][Full Text] [Related]
14. Cinnamaldehydes inhibit cyclin dependent kinase 4/cyclin D1.
Jeong HW; Kim MR; Son KH; Han MY; Ha JH; Garnier M; Meijer L; Kwon BM
Bioorg Med Chem Lett; 2000 Aug; 10(16):1819-22. PubMed ID: 10969976
[TBL] [Abstract][Full Text] [Related]
15. 2-Aminoquinazoline inhibitors of cyclin-dependent kinases.
Bathini Y; Singh I; Harvey PJ; Keller PR; Singh R; Micetich RG; Fry DW; Dobrusin EM; Toogood PL
Bioorg Med Chem Lett; 2005 Sep; 15(17):3881-5. PubMed ID: 15993068
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate.
Liang YC; Lin-Shiau SY; Chen CF; Lin JK
J Cell Biochem; 1999 Oct; 75(1):1-12. PubMed ID: 10462699
[TBL] [Abstract][Full Text] [Related]
17. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.
Kim KS; Sack JS; Tokarski JS; Qian L; Chao ST; Leith L; Kelly YF; Misra RN; Hunt JT; Kimball SD; Humphreys WG; Wautlet BS; Mulheron JG; Webster KR
J Med Chem; 2000 Nov; 43(22):4126-34. PubMed ID: 11063609
[TBL] [Abstract][Full Text] [Related]
18. Identification of selective inhibitors of cyclin dependent kinase 4.
Carini DJ; Kaltenbach RF; Liu J; Benfield PA; Boylan J; Boisclair M; Brizuela L; Burton CR; Cox S; Grafstrom R; Harrison BA; Harrison K; Akamike E; Markwalder JA; Nakano Y; Seitz SP; Sharp DM; Trainor GL; Sielecki TM
Bioorg Med Chem Lett; 2001 Aug; 11(16):2209-11. PubMed ID: 11514172
[TBL] [Abstract][Full Text] [Related]
19. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
Kubo A; Nakagawa K; Varma RK; Conrad NK; Cheng JQ; Lee WC; Testa JR; Johnson BE; Kaye FJ; Kelley MJ
Clin Cancer Res; 1999 Dec; 5(12):4279-86. PubMed ID: 10632371
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
